Cargando…

BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice

Detalles Bibliográficos
Autores principales:	Cervellati, Carlo, Valacchi, Giuseppe, Zuliani, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374572/ https://www.ncbi.nlm.nih.gov/pubmed/33907020 http://dx.doi.org/10.4103/1673-5374.313041

Ejemplares similares

Early elevation of BACE1 in dementia
por: Cervellati, Carlo, et al.
Publicado: (2021)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

OxInflammation in Alzheimer’s disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease
por: Zuliani, Giovanni, et al.
Publicado: (2020)

Frontier on Alzheimer’s Disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Serum zonulin levels are increased in Alzheimer’s disease but not in vascular dementia
por: Boschetti, Elisa, et al.
Publicado: (2023)

Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)
por: Wood, Paul L., et al.
Publicado: (2015)

Systemic Oxidative Stress and Conversion to Dementia of Elderly Patients with Mild Cognitive Impairment
por: Cervellati, Carlo, et al.
Publicado: (2014)

Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia
por: Romani, Arianna, et al.
Publicado: (2020)

Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer's Disease
por: Zuliani, Giovanni, et al.
Publicado: (2018)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future
por: Mok, Vincent C.T., et al.
Publicado: (2020)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia
por: Zuliani, Giovanni, et al.
Publicado: (2023)

Dementia in the oldest old: Beyond Alzheimer disease
por: Pierce, Aimee L., et al.
Publicado: (2017)

Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review
por: Zimetti, Francesca, et al.
Publicado: (2021)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

Risk of dementia in patients with atrial fibrillation: Short versus long follow‐up. A systematic review and meta‐analysis
por: Zuin, Marco, et al.
Publicado: (2021)

BACE1, the Alzheimer's beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2012)

BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2013)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
por: Vassar, Robert
Publicado: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

Cutaneous responses to environmental stressors
por: Valacchi, Giuseppe, et al.
Publicado: (2012)

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus
por: Li, Nuomin, et al.
Publicado: (2022)

Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis
por: Zuin, Marco, et al.
Publicado: (2021)

OxInflammation: From Subclinical Condition to Pathological Biomarker
por: Valacchi, Giuseppe, et al.
Publicado: (2018)

Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome()
por: Mok, Kin Y., et al.
Publicado: (2014)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Paraoxonase-1 and Other HDL Accessory Proteins in Neurological Diseases
por: Marsillach, Judit, et al.
Publicado: (2021)

Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease
por: Decourt, Boris, et al.
Publicado: (2013)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
por: Neumann, Ulf, et al.
Publicado: (2018)

BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
por: Bazzari, Firas H., et al.
Publicado: (2022)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
por: Timmers, Maarten, et al.
Publicado: (2017)

Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID‐19 pandemic
por: Meyers, Emily A., et al.
Publicado: (2021)

Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
por: Zuin, Marco, et al.
Publicado: (2021)

Reconsidering frameworks of Alzheimer's dementia when assessing psychosocial outcomes
por: Gaugler, Joseph E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fvbf17cfajq8ulv42gl09h6rqq